NFKBIZ（NF-Kappa-B Inhibitor Zeta）是NF-κB信号通路的重要调控基因，属于IκB家族（Inhibitor of Kappa B家族），该家族成员通过抑制NF-κB转录因子的活性来调控炎症、免疫反应和细胞存活等过程。NFKBIZ编码的蛋白IκB-ζ（也称为MAIL或IL-1诱导的NF-κB抑制剂）与其他IκB蛋白不同，它不直接结合NF-κB抑制其入核，而是在细胞核内选择性调控特定NF-κB靶基因的表达，既能增强某些促炎基因（如IL-6、IL-12）的转录，又能抑制其他基因的活性。NFKBIZ主要在免疫细胞（如巨噬细胞、B细胞）中表达，受TLR或IL-1受体信号激活后迅速诱导产生，是先天免疫和炎症反应的关键调节分子。NFKBIZ突变可能导致其功能异常，与多种炎症性疾病相关，如类风湿性关节炎、银屑病和炎症性肠病（IBD）。研究发现NFKBIZ基因多态性与这些疾病的易感性显著相关。NFKBIZ过表达会增强NF-κB依赖性炎症因子的产生，加剧炎症反应，而敲除或低表达则导致免疫应答缺陷，增加感染风险，同时可能减轻自身免疫疾病的症状。在癌症中，NFKBIZ的异常表达可能通过调控肿瘤微环境的炎症状态影响肿瘤进展，例如在弥漫大B细胞淋巴瘤（DLBCL）中高表达与不良预后相关。IκB家族共性包括含有多个ANK重复结构域以介导蛋白相互作用，且多数成员通过遮蔽NF-κB的核定位信号抑制其活性，但NFKBIZ的独特核内作用机制使其成为家族中的功能特化成员。该基因的调控网络还涉及与NF-κB亚基（如p50）形成复合物，进一步精细调节下游基因表达，凸显其在免疫平衡中的枢纽地位。

此基因是锚蛋白重复家族的成员，并且是由脂多糖（LPS）诱导的。它包含与IκB的家族蛋白的锚蛋白重复序列??，股高序列相似性的编码产物的C末端部分。后者是公知的通过它们与通过锚蛋白重复结构域NF-κB蛋白的相互作用中发挥炎症反应对LPS的作用。在小鼠的研究表明，该基因产物是核我κB的蛋白之一和IL-6产生的活化剂。已发现该基因编码不同亚型的两个转录变异体。 [由RefSeq的，2008年7月提供]

NFKBIZ, encoding the protein IκB-ζ (also known as MAIL or IL-1-induced NF-κB inhibitor), is a specialized member of the IκB (Inhibitor of Kappa B) family that plays a distinct and nuanced role in the regulation of the NF-κB signaling pathway. Unlike canonical IκB proteins that typically sequester NF-κB transcription factors in the cytoplasm to prevent their nuclear translocation, IκB-ζ functions primarily within the nucleus, where it selectively modulates the transcriptional activity of specific NF-κB target genes rather than broadly inhibiting the pathway. This nuclear-specific mechanism allows IκB-ζ to act as a context-dependent regulator; it can enhance the transcription of pro-inflammatory cytokines such as IL-6 and IL-12 while simultaneously repressing other NF-κB-dependent genes, thereby fine-tuning the inflammatory response. Structurally, IκB-ζ retains the characteristic ankyrin repeat domains found in other IκB family members, which facilitate protein-protein interactions, and it forms complexes with specific NF-κB subunits, such as p50, to precisely control downstream gene expression. The expression of NFKBIZ is rapidly induced in immune cells, including macrophages and B cells, following activation by toll-like receptor (TLR) or IL-1 receptor signaling, establishing it as a critical mediator of innate immunity and acute inflammation. Consequently, dysregulation of NFKBIZ has significant clinical implications; its overexpression can exacerbate inflammatory conditions by amplifying NF-κB-dependent cytokine production, whereas its deficiency or low expression may lead to immunodeficiency and increased susceptibility to infections, although it might concurrently alleviate symptoms of autoimmune disorders. Genetic polymorphisms in NFKBIZ have been significantly associated with the susceptibility to various chronic inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease (IBD). Furthermore, aberrant expression of NFKBIZ in the tumor microenvironment can influence cancer progression, with high levels observed in diffuse large B-cell lymphoma (DLBCL) correlating with poor patient prognosis, highlighting the gene's pivotal role in maintaining immune homeostasis and its potential as a therapeutic target in both inflammatory and oncological contexts.

Loading comments...